share_log

AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

AbbVie | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

艾伯維公司 | S-8:員工福利計劃證券登記
美股SEC公告 ·  2024/11/04 15:19

Moomoo AI 已提取核心訊息

AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission (SEC) on November 4, 2024. This filing is to register additional deferred compensation obligations under two of its plans: the AbbVie Deferred Compensation Plan and the AbbVie Deferred Compensation Plan Plus. The registration relates to securities of the same class as those previously registered and incorporates by reference the contents of a prior Registration Statement filed on November 4, 2022. The company, identified as a large accelerated filer, has included various exhibits in the filing, such as its Amended and Restated Certificate of Incorporation and its Deferred Compensation Plans. The filing also includes the consent of Ernst & Young LLP and Kirkland & Ellis LLP, with the latter providing a legal opinion. AbbVie's executive team, including CEO Robert A. Michael and CFO Scott T. Reents, have signed the Registration Statement, affirming the company's compliance with the requirements for filing on Form S-8.
AbbVie Inc., a biopharmaceutical company incorporated in Delaware, has filed a Registration Statement on Form S-8 with the United States Securities and Exchange Commission (SEC) on November 4, 2024. This filing is to register additional deferred compensation obligations under two of its plans: the AbbVie Deferred Compensation Plan and the AbbVie Deferred Compensation Plan Plus. The registration relates to securities of the same class as those previously registered and incorporates by reference the contents of a prior Registration Statement filed on November 4, 2022. The company, identified as a large accelerated filer, has included various exhibits in the filing, such as its Amended and Restated Certificate of Incorporation and its Deferred Compensation Plans. The filing also includes the consent of Ernst & Young LLP and Kirkland & Ellis LLP, with the latter providing a legal opinion. AbbVie's executive team, including CEO Robert A. Michael and CFO Scott T. Reents, have signed the Registration Statement, affirming the company's compliance with the requirements for filing on Form S-8.
艾伯維公司是一家註冊在特拉華州的生物製藥公司,於2024年11月4日向美國證券交易委員會(SEC)提交了一份S-8表格的登記聲明。這一申報旨在爲其兩個計劃:艾伯維遞延報酬計劃和艾伯維遞延報酬計劃Plus註冊額外的遞延報酬義務。該註冊涉及與先前註冊的同類證券,並通過引用了於2022年11月4日提交的之前登記聲明的內容。該公司被確定爲大型加速文件提交者,並已在申報中包含了各種附件,如其經修訂的公司章程和遞延報酬計劃。該申報還包括安永會計師事務所和柯克蘭律師事務所的同意書,後者提供了法律意見。艾伯維的高管團隊,包括CEO羅伯特·A·邁克爾和CFO斯科特·T·裏恩茨,已簽署了登記聲明,確認公司符合S-8表格提交的要求。
艾伯維公司是一家註冊在特拉華州的生物製藥公司,於2024年11月4日向美國證券交易委員會(SEC)提交了一份S-8表格的登記聲明。這一申報旨在爲其兩個計劃:艾伯維遞延報酬計劃和艾伯維遞延報酬計劃Plus註冊額外的遞延報酬義務。該註冊涉及與先前註冊的同類證券,並通過引用了於2022年11月4日提交的之前登記聲明的內容。該公司被確定爲大型加速文件提交者,並已在申報中包含了各種附件,如其經修訂的公司章程和遞延報酬計劃。該申報還包括安永會計師事務所和柯克蘭律師事務所的同意書,後者提供了法律意見。艾伯維的高管團隊,包括CEO羅伯特·A·邁克爾和CFO斯科特·T·裏恩茨,已簽署了登記聲明,確認公司符合S-8表格提交的要求。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息